Form 10-Q · Quarterly report
Zebra Technologies 10-Q, filed Nov 3, 2026
- Filed
- CIK
- 0000877212
- Accession no.
- 0001628280-26-069444
Summary
Zebra Technologies reported third-quarter 2026 net sales of $1.61 billion, up 22.3% from $1.32 billion a year earlier, with operating income of $237 million and net income of $164 million, or $3.43 per diluted share, versus $101 million, or $1.97 per diluted share, in the prior-year quarter. The company said the quarter's gross margin fell to 45.7% from 48.0%, mainly on higher memory costs and unfavorable business mix, while organic net sales rose 11.3% excluding currency and acquisition effects.
Key points
- Consolidated organic net sales grew 11.3% in the quarter, after adjusting for foreign currency translation and acquisitions and dispositions.
- Gross margin declined to 45.7% from 48.0% a year earlier, primarily due to increased memory costs and unfavorable business mix.
- Operating expenses rose to $501 million from $451 million, driven in part by the inclusion of Elo Touch operating expenses including intangible asset amortization.
- The company repurchased $643 million of common shares year to date, including $75 million in the third quarter.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Overview We are a global leader in the Automatic Identification and Data Capture (“AIDC”) industry. The AIDC market consists of mobile computing, data capture, radio frequency identification devices (“RFID”), thermal barcode printing, and other workflow automation products and services. The Company’s offerings are proven to help our customers and end-users digitize and automate their workflows to achieve their critical business objectives, including improved productivity and operational efficiency, optimized regulatory compliance, and better customer experiences. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.